Authors

Latest:

Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDS

Somedeb Ball, MBBS, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes.

Bill W. Loo, MD

Latest:

Exciting NSCLC Data Updates from ESMO 2022

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE

Latest:

Dr Cruz-Correa on the FDA Approval of Tislelizumab Plus Chemotherapy for Metastatic Gastric/GEJ Cancer

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab plus chemotherapy for metastatic gastric or GEJ adenocarcinoma.

B. Hilda Ye, PhD

Latest:

Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features

Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.

Roswell Park Comprehensive Cancer Center

Latest:

Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer

Laboratory research led by Anna Bianchi-Smiraglia, PhD, reveals therapeutic target in metabolic enzyme IMPDH2.

Efrat Dotan, MD

Latest:

Dr Dotan on Treating Geriatric Patients With Gastroesophageal Cancer

Efrat Dotan, MD, discusses a retrospective study aiming to understand the needs of geriatric patients with gastroesophageal cancer.

Nicole Rich, MD

Latest:

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

David M. O'Malley, MD, The Ohio State University

Latest:

Dr. O’Malley on the Utility of Chemoimmunotherapy in Ovarian Cancer

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

Firas Badin, MD, Baptist Health

Latest:

Updates in Immunotherapy for Advanced Thoracic Malignancies

Anna R. Minchom MD, BCh, MB, MRCP

Latest:

Dr Minchom on the Safety of Subcutaneous Amivantamab in Advanced Solid Tumors

Anna R. Minchom MD, BCh, MB, MRCP, discusses the safety and recommended phase 2 doses of subcutaneous amivantamab-vmjw for patients with advanced solid tumors in the phase 1b PALOMA trial.

Paolo Tarantino, MD

Latest:

Dr Tarantino on Advances Allowing for Tailored Treatment in HER2+ Breast Cancer

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Russell J. Ledet, PhD

Latest:

A Prayer for a More Equitable Future

Russell J. Ledet, PhD, discusses being a Black man in the field of oncology.

Adam L. Johnson, MD

Latest:

The Mullin Sisters

A breast surgical oncology fellow tells the story of how 3 women in his family helped shape his career and provide a purpose for his passion.

Jaime Schneider, MD, PhD

Latest:

Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLC

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.

Jayesh Desai, MBBS, FRACP

Latest:

Phase IB Study of GDC-6036 in Combination with Cetuximab in Patients With Colorectal Cancer (CRC) With KRAS G12C Mutation

Jayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.

Bharat Sanders

Latest:

Taking Back Our Empathy: Reflections on a New Model of Medical Education

Bharat Sanders sheds light on how patient-centered medical education put him behind the eyes of the patient and fundamentally changed the way he practices medicine.

Monalisa Ghosh, MD

Latest:

Dr. Ghosh on the Role of Off-the-Shelf CAR T-Cell Therapy in Myeloma

Monalisa Ghosh, MD, discusses the role of off-the-shelf CAR T-cell therapy in patients with multiple myeloma.

Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center

Latest:

Dr Raghav on a Phase 2 Study of ABBV-400 Plus Fluorouracil, Folinic Acid, and Bevacizumab in Pretreated Metastatic CRC

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.

Christine Bestvina, MD, University of Chicago

Latest:

Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.

Amanda Bloomer, PhD

Latest:

Dr Bloomer on the Rationale for the ColoCare Study in Newly Diagnosed CRC

Amanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.